Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs PEMETREXED DISODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Mesothelioma: In combination with cisplatin for treatment of malignant pleural mesothelioma in patients who are not candidates for curative surgery.,Non-small cell lung cancer: First-line treatment in combination with cisplatin for locally advanced or metastatic nonsquamous NSCLC.,Non-small cell lung cancer: Maintenance monotherapy for locally advanced or metastatic nonsquamous NSCLC with stable disease after 4 cycles of platinum-based chemotherapy.,Non-small cell lung cancer: Second-line treatment as monotherapy for locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Terminal half-life is 3.5 hours in patients with normal renal function. Increases in renal impairment (up to 20 hours if Cr Cl <45 m L/min).
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Pemetrexed is primarily eliminated unchanged in urine. It undergoes minimal hepatic metabolism. The drug is a substrate for multidrug resistance-associated proteins (MRPs) and possibly other transporters.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Primarily renal excretion (70-90% as unchanged drug within 24 hours). Biliary/fecal excretion accounts for <5%.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
~81% bound primarily to albumin.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Vd = 0.2 L/kg (approximately 16 L in adults). Indicates limited distribution to extravascular spaces.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Intravenous: 100% (only route of administration).
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Cr Cl ≥45 m L/min: No adjustment. Cr Cl <45 m L/min: Not recommended. For Cr Cl 40-59 m L/min, no adjustment; Cr Cl <40 m L/min, not recommended based on clinical trial criteria.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
No specific dose adjustment guidelines for hepatic impairment. Use caution with bilirubin >1.5 times ULN and/or AST/ALT >3 times ULN. Child-Pugh classification not formally studied.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Safety and efficacy not established in pediatric patients. No recommended dosing.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
No specific dose adjustment recommended based on age alone. Monitor renal function closely as elderly patients may have reduced Cr Cl.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Pemetrexed can cause severe myelosuppression, which may lead to infection and bleeding. Patients must be monitored for bone marrow suppression. Adequate folic acid and vitamin B12 supplementation is required to reduce toxicity.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Bone marrow suppression: Monitor blood counts regularly; dose adjust or hold for severe neutropenia, thrombocytopenia, or anemia.,Renal toxicity: Avoid in creatinine clearance <45 m L/min; monitor renal function.,Gastrointestinal toxicity: Severe diarrhea, mucositis may occur; manage with supportive care.,Dermatologic toxicity: Severe rash may occur; premedicate with corticosteroids.,Radiation recall: Risk of severe radiation recall in patients who have received prior radiotherapy.,Folic acid and vitamin B12 supplementation: Required to reduce hematologic and gastrointestinal toxicity.,Pregnancy: Can cause fetal harm; advise women of reproductive potential to use effective contraception.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
History of severe hypersensitivity reaction to pemetrexed or any excipient.,Patients with creatinine clearance <45 m L/min (contraindicated for use in combination with cisplatin due to increased toxicity).
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
No known food interactions. Avoid folic acid-containing supplements beyond prescribed dose as they may interfere with pemetrexed activity. Maintain adequate hydration.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Pemetrexed is contraindicated in pregnancy. It is an antifolate antimetabolite that inhibits thymidylate synthase and other folate-dependent enzymes, essential for DNA synthesis and cell division. Based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregnant woman. First trimester: High risk of teratogenicity (neural tube defects, craniofacial, cardiovascular malformations) due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal death. Embryofetal toxicity and teratogenicity have been demonstrated in mice and rats at doses lower than the human therapeutic dose.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No data available on the presence of pemetrexed in human milk, its effects on the breastfed infant, or on milk production. Due to the potential for serious adverse reactions in the breastfed infant (including myelosuppression, gastrointestinal toxicity, and carcinogenesis), breastfeeding is not recommended during therapy and for at least 1 week after the last dose. The M/P ratio is unknown.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
No specific dose adjustment guidelines exist for pemetrexed in pregnancy because its use is contraindicated. However, pregnancy may alter the pharmacokinetics of pemetrexed due to increased renal clearance (increased glomerular filtration rate) and expanded plasma volume, potentially reducing drug exposure. No formal studies have been conducted. Given the high risk of fetal harm, pemetrexed should not be used in pregnant women. If treatment is deemed necessary for a life-threatening condition, the risks versus benefits must be considered, and dosing adjustments cannot be recommended due to lack of data.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Administer folic acid 350-1000 mcg orally daily beginning 7 days before first dose and continuing throughout therapy. Administer vitamin B12 1000 mcg IM 1 week before first dose and every 3 cycles thereafter. Premedicate with dexamethasone 4 mg orally twice daily the day before, day of, and day after each dose to reduce cutaneous reactions. Monitor for myelosuppression, especially neutropenia; dose reduce as needed. Contraindicated in patients with creatinine clearance <45 m L/min. Avoid NSAIDs 2-5 days before and 2 days after pemetrexed due to increased toxicity.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
Take folic acid supplements daily, starting 7 days before your first treatment and continuing until your doctor stops it.,You will receive vitamin B12 injections before your first dose and then every 9 weeks.,Take a steroid medication (dexamethasone) as prescribed the day before, day of, and day after each infusion to prevent skin reactions.,Avoid taking NSAIDs (like ibuprofen or naproxen) for at least 2-5 days before and 2 days after your pemetrexed infusion.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or severe fatigue immediately.,Drink plenty of fluids unless otherwise instructed. There are no specific dietary restrictions, but maintain a balanced diet.,Use effective contraception during treatment and for at least 6 months after the last dose (females) or 3 months (males). Do not breastfeed during treatment.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
"The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide."
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
"Pemetrexed may increase the immunosuppressive activities of Fingolimod."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs PEMETREXED DISODIUM, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. PEMETREXED DISODIUM is a Antineoplastic Antifolate that works by Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and PEMETREXED DISODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of PEMETREXED DISODIUM is: 500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTANIL and PEMETREXED DISODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. PEMETREXED DISODIUM is classified as Category C. Pemetrexed is contraindicated in pregnancy. It is an antifolate antimetabolite that inhibits thymidylate synthase and other folate-dependent enzymes, essential for DNA synthesis an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.